NEU 2.37% $19.39 neuren pharmaceuticals limited

Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-28

  1. 179 Posts.
    lightbulb Created with Sketch. 97
    And adding to my post, after the trofinetide approval, in my opinion, Neuren must focus immediately on proving NNZ2591 in other rare syndromes in mouse models, in anticipation of successful 3 or 4 P2 trials results which may come around the middle of 2023. Proving NNZ2591 in additional rare syndromes in mouse models would be other significant point when it comes to negotiating US rights for NNZ2591 after P2 trials.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$19.39
Change
-0.470(2.37%)
Mkt cap ! $2.478B
Open High Low Value Volume
$19.70 $19.77 $19.28 $10.38M 534.0K

Buyers (Bids)

No. Vol. Price($)
3 2680 $19.35
 

Sellers (Offers)

Price($) Vol. No.
$19.41 362 1
View Market Depth
Last trade - 16.10pm 30/07/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.